During Q4 2018 the big money sentiment decreased to 1.08. That’s change of 0.68, from 2018Q3’s 1.76. 19 investors sold all, 46 reduced holdings as SPPI ratio fall. 51 rose stakes while 19 funds took stakes. Funds hold 82.09 million shares thus 3.65% less from 2018Q3’s 85.20 million shares. 1.00M were accumulated by Dimensional Fund Advsr L P. Arizona State Retirement Sys owns 0.02% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 156,413 shs. Proshare Advisors Ltd owns 49,700 shs. State Bank Of New York Mellon stated it has 0% of its capital in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Fisher Asset Ltd Llc holds 180,663 shs. Principal Gp owns 853,294 shs. Ashford Cap Management Incorporated has 0.42% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Barclays Plc stated it has 58,724 shs or 0% of all its holdings. Geode Limited Liability Company invested in 1.16M shs. Point72 Asset Mgmt Lp has 0.02% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 539,200 shs. California State Teachers Retirement stated it has 157,930 shs. Voya Mngmt Ltd Liability Corp has invested 0.02% of its capital in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Profund Advsr Limited Liability Co, a Maryland-based fund reported 31,401 shs. Great West Life Assurance Communications Can owns 140,269 shs for 0% of their capital. Sector Pension Board reported 0.01% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI).

SPPI registered $1.54 million net activity with 0 insider purchases and 12 selling transactions since October 9, 2018. MAIDA ANTHONY E III sold $94,758 worth of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) or 7,250 shs on Thursday, November 8. Vyas Dolatrai also sold $63,826 worth of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) shs. On Thursday, February 7 the insider McGahan Keith M sold $27,541. GUSTAFSON KURT A sold 3,207 shs worth $33,471. Riga Thomas J sold $109,578 worth of stock. On Wednesday, January 16 Turgeon Joseph W. sold $53,135 worth of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) or 5,091 shs.

Consonance Capital Management Lp’s holdings in Spectrum Pharmaceuticals Inc (SPPI) is reduced by 49.07% based on its latest 2018Q4 regulatory filing with the SEC. 2.86M shares were sold by Consonance Capital Management Lp as the company’s stock declined 21.14% while stock markets rallied. At the end of 2018Q4, the 2.97M shares of the health care company held by the hedge fund were priced at $25.98 million, down from 5.83 million at the end of the previous reported quarter. $1.23 billion is Spectrum Pharmaceuticals Inc’s market cap. The stock increased 2.09% or $0.23 during the last trading session, hitting $11.26.Currently Spectrum Pharmaceuticals, Inc. is downtrending after 47.79% change in last April 6, 2018. SPPI has 797,273 shares volume. SPPI underperformed by 52.16% the S&P 500.

According to a filing Consonance Capital Management Lp upped its stake in Uniqure Nv (NASDAQ:QURE) by 851,161 shares to 1.90 million shares, valued at $54.65M in 2018Q4. The fund manages about $513.80M and $1.36 billion US Long portfolio. Consonance Capital Management Lp has risen its stake in Exelixis Inc (NASDAQ:EXEL) and also increased its holding in United Therapeutics Corp Del (NASDAQ:UTHR) by 238,302 shares in the quarter, for a total of 1.10M shares.

On May, 2 WallStreet expected Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)’s earnings release, RTT reports. Analysts predict $-0.21 earnings per share, which is $0.02 down or 10.53 % from 2018’s $-0.19 earnings per share. Analysts at Wall Street see Spectrum Pharmaceuticals, Inc.’s -38.24 % EPS growth compared to $-0.34 earnings per share for previous quarter.

For more Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) news announced briefly go to: Globenewswire.com, Benzinga.com, Seekingalpha.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Report: Exploring Fundamental Drivers Behind ON Semiconductor, Pilgrim’s Pride, Merck & Co., Healthcare Services Group, Genomic Health, and Spectrum Pharmaceuticals — New Horizons, Emerging Trends, and Upcoming Developments – GlobeNewswire” announced on March 25, 2019, “32 Stocks Moving In Friday’s Pre-Market Session – Benzinga” on March 15, 2019, “Spectrum Suffers BLA Setback, But Based On Deadline, It Was For The Better – Seeking Alpha” with a publish date: March 18, 2019, “BMO likes Amgen and Gilead in premarket analyst action – Seeking Alpha” and the last “Spectrum withdraws U.S. marketing application for Rolontis; shares down 8% premarket – Seeking Alpha” with publication date: March 15, 2019.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Ratings Coverage

A total of 4 analysts rate Spectrum Pharmaceuticals (NASDAQ:SPPI) as follows: 4 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:SPPI) has 7 ratings reports on Apr 6, 2019 according to StockzIntelligence. On Monday, November 12 the firm has “Buy” rating by FBR Capital given. On Friday, March 15 the stock has “Buy” rating by H.C. Wainwright. On Friday, March 15 the stock has “Buy” rating by Cantor Fitzgerald. On Friday, March 15 Jefferies initiated Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) rating. Jefferies has “Buy” rating and $21 target. On Friday, March 1 the firm has “Buy” rating by H.C. Wainwright given. On Thursday, February 28 the rating was maintained by Cantor Fitzgerald with “Buy”.